This article explores how next-generation vaccines are expanding beyond infectious disease to target chronic conditions while ...

Biotechnology instruments market size was valued at USD 92.12 billion in 2025 and is projected to hit the market valuation of USD 141.70 billion by 2035 at a CAGR of 4.4% during the forecast period ...

Vaxxas has appointed former Merck Global Vaccines president David Peacock as chief executive officer (CEO), marking a step in ...

Brisbane-based Vaxxas has appointed David Peacock to lead the push to bring its vaccine patch technology to market.

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.